Recent Comments

Comment RSS

Atorvastatin News and Research RSS Feed - Atorvastatin News and Research

High blood pressure: A major risk factor for stroke and heart disease

20. November 2009 01:25
Today, Jamieson Laboratories, in partnership with the Victorian Order of Nurses (VON), is holding a one day Blood Pressure Blitz in Toronto's underground PATH system in an effort to educate consumers about the number one risk factor for stroke and a major risk factor of heart disease. [More]

Dual niacin-statin therapy improves blood cholesterol levels but does not diminish plaque buildup

19. November 2009 00:47
The routine prescription of extended-release niacin, a B vitamin (1,500 milligrams daily), in combination with traditional cholesterol-lowering therapy offers no extra benefit in correcting arterial narrowing and diminishing plaque buildup in seniors who already have coronary artery disease, a new vascular imaging study from Johns Hopkins experts shows. [More]

Findings of Merck's anacetrapib phase IIb study presented at the AHA sessions

18. November 2009 05:33
In a phase IIb study in 589 patients with primary hypercholesterolemia or mixed hyperlipidemia treated with anacetrapib as monotherapy or co-administered with atorvastatin, there were persistent lipid effects in the higher dose arms in both the monotherapy and co-administration treatment groups eight weeks after stopping active therapy with anacetrapib. [More]

Pediatric data for Pfizer's Lipitor submitted to the EMEA

18. November 2009 04:58
Pfizer Inc announced it has submitted pediatric data for Lipitor® (atorvastatin) to the European Medicines Agency (EMEA). Pfizer has also developed a new chewable form of Lipitor, including a pediatric-appropriate 5 mg dose, which is part of this submission. [More]

Upsher-Smith Laboratories publishes results of SLIM Study

17. November 2009 04:10
Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology. [More]

NicOx reports top-line results from first-in-man study of its NO-donating HMG-CoA Reductase Inhibitor

13. November 2009 01:45
NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile. [More]

Statins may have negative effects on some cardiac patients, says study

4. November 2009 22:57
Although statins are widely used to prevent heart attacks, strokes, and other cardiovascular disorders, new research shows that the class of drugs may actually have negative effects on some cardiac patients. A new study presented at CHEST 2009, the 75th annual international scientific assembly of the American College of Chest Physicians (ACCP), found that statins have beneficial effects on patients with systolic heart failure (SHF), but those with diastolic heart failure (DHF) experienced the opposite effect, including increased dyspnea, fatigue, and decreased exercise tolerance. [More]

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

29. October 2009 10:30
The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country. [More]

Upsher-Smith Laboratories publishes data on Slo-Niacin and Lipitor combination study

28. October 2009 05:03
Results of the SLIM Study ("Slo-Niacin® and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia") were recently published in the Journal of Clinical Lipidology. [More]

Study reveals that adding ezetimibe to atorvastatin aids in reducing cholesterol

27. October 2009 07:18
Edmonton - Adding ezetimibe to atorvastatin significantly boosted the attainment of lipid targets as specified by both Canadian and European guidelines in elderly patients aged 65 and older and the combination produced superior results than simply increasing the dose of atorvastatin alone, Dr. Christian Constance told the Canadian Cardiovascular Congress 2009, co-hosted by the Heart and Stroke Foundation and the Canadian Cardiovascular Society. [More]

Comprehensive analysis of statin drug market

21. October 2009 05:03
Reportlinker.com announces that a new market research report is available in its catalogue: Statins: The World Market, 2009-2024 [More]

Actavis' clients launch generic Atorvastatin in Spain

1. October 2009 19:55
Actavis Group, the international generic pharmaceuticals company, today announced that its third-party sales division, Medis, has delivered 30 million tablets of Atorvastatin to its clients in Spain. This is the first generic version of the blockbuster molecule to reach the Spanish market. [More]

Posted in: Pharmaceutical News

Tags: , , , ,

Combination of LIVALO and itraconazole drugs shows no adverse reactions

2. September 2009 08:14
... [More]

High-density lipoprotein cholesterol concentrations increased in patients treated with LIVALO

2. September 2009 00:03
New data presented today showed that in patients treated with LIVALO (pitavastatin), high-density lipoprotein cholesterol (HDL-C) concentrations increased, and nearly three-fourths of patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results sustained over 52 weeks. [More]

Traditional lipid risk factors to be strong predictors of cardiovascular events according to a study

1. September 2009 04:24
For patients with established heart disease who were treated with a statin, 18 novel biomarkers including C-reactive protein (CRP) did not predict future cardiovascular events such as heart attack and stroke, according to results of an analysis presented today at the 2009 European Society of Cardiology Congress in Barcelona, Spain. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.